Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis
Authors Gaebler JA, Soto-Campos G, Alperin P, Cohen M, Blickensderfer A, Wintle M, Maggs D, Hoogwerf B, Han J, Pencek R, Peskin B
Published Date April 2012 Volume 2012:8 Pages 255—264
Received 1 December 2011, Accepted 17 February 2012, Published 23 April 2012
Julia A Gaebler1, Gerardo Soto-Campos2, Peter Alperin2, Marc Cohen2, Amy Blickensderfer1, Matthew Wintle1, David Maggs1, Byron Hoogwerf3, Jenny Han1, Richard Pencek1, Barbara Peskin2
1Amylin Pharmaceuticals, Inc, San Diego CA, 2Archimedes Inc, San Francisco CA, 3Eli Lilly and Company, Indianapolis, IN, USA
Background: Patients with type 2 diabetes (T2DM) are at risk of long-term vascular complications. In trials, exenatide once weekly (ExQW), a GLP-1R agonist, improved glycemia, weight, blood pressure (BP), and lipids in patients with T2DM. We simulated potential effects of ExQW on vascular complications, survival, and medical costs over 20 years versus standard therapies.
Patients and methods: The Archimedes model was used to assess outcomes for ~25,000 virtual patients with T2DM (NHANES 1999–2006 [metformin ± sulfonylureas, age 57 years, body mass index 33 kg/m2, weight 94 kg, duration T2DM 9 years, hemoglobin A1c [A1C] 8.1%]). The effects of three treatment strategies were modeled and compared to moderate-adherence insulin therapy: advancement to high-adherence insulin at A1C ≥ 8% (treat to target A1C < 7%) and addition of pioglitazone (PIO) or ExQW from simulation start. ExQW effects on A1C, weight, BP, and lipids were modeled from clinical trial data. Costs, inflated to represent 2010 $US, were derived from Medicare data, Drugstore.com, and publications. As ExQW was investigational, we omitted ExQW, PIO, and insulin pharmacy costs.
Results: By year 1, ExQW treatment decreased A1C (~1.5%), weight (~2 kg), and systolic BP (~5 mmHg). PIO and high-adherence insulin decreased A1C by ~1%, increased weight, and did not affect systolic BP. After 20 years, A1C was ~7% with all strategies. ExQW decreased rates of cardiovascular and microvascular complications more than PIO or high-adherence insulin versus moderate-adherence insulin. Over 20 years, ExQW treatment resulted in increased quality-adjusted life-years (QALYs) of ~0.3 years/person and cost savings of $469/life-year versus moderate adherence insulin. For PIO or high-adherence insulin, QALYs were virtually unchanged, and costs/life-year versus moderate-adherence insulin increased by $69 and $87, respectively.
Conclusions: This long-term simulation demonstrated that ExQW treatment may decrease rates of cardiovascular and some microvascular complications of T2DM. Increased QALYs, and decreased costs were also projected.
Keywords: diabetes, modeling, exenatide, pioglitazone, insulin, cardiovascular risk
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Readers of this article also read:
Kinematic analysis of motor strategies in frail aged adults during the Timed Up and Go: how to spot the motor frailty?
Hassani A, Kubicki A, Brost V, Mourey F, Yang F
Published Date: 26 February 2015
Lower irritation microemulsion-based rotigotine gel: formulation optimization and in vitro and in vivo studies
Wang Z, Mu HJ, Zhang XM, Ma PK, Lian SN, Zhang FP, Chu SY, Zhang WW, Wang AP, Wang WY, Sun KX
Published Date: 14 January 2015
DiNicolantonio JJ, O’Keefe JH
Published Date: 30 August 2014
Hundal R, Shaffer EA
Published Date: 7 March 2014
HbA1c for diagnosis of type 2 diabetes. Is there an optimal cut point to assess high risk of diabetes complications, and how well does the 6.5% cutoff perform?
Kowall B, Rathmann W
Published Date: 29 November 2013
Low-weight polyethylenimine cross-linked 2-hydroxypopyl-ß-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA
Li JM, Wang YY, Zhang W, Su H, Ji LN, Mao ZW
Published Date: 5 June 2013
Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
Nielsen SA, McDonald MB, Majmudar PA
Published Date: 17 January 2013
Basic training module for vitreoretinal surgery and the Casey Eye Institute Vitrectomy Indices Tool for Skills Assessment
Yeh S, Chan-Kai BT, Lauer AK
Published Date: 1 September 2011
Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention
Shailja V Parikh, Ellen C Keeley
Published Date: 19 August 2009
David J Muzina
Published Date: 19 May 2009